Diffuse large B-cell lymphoma · 13 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
R-IFE Variant #01 | — | R 47 799 | 14d | — | — | ~2 | ~R 95 598 indirect | — |
Z-BEAM Variant #01 Partial | — | R 30 964 | — | — | — | ~1 | ~R 30 964 indirect | — |
CBV-Mx Variant #01 Partial | — | R 16 619 | — | — | — | ~1 | ~R 16 619 indirect | — |
CBV Variant #01 Partial | — | R 9 597 | — | — | — | 1 | R 9 597 PFS proxy | 2 |
Cyclophosphamide and TBI Variant #01 | — | R 1 176 | — | — | ~90.0 mo | ~1 | ~R 1 176 PFS proxy · indirect | 1 |
Cytarabine and Methotrexate (CYM) Variant #03 | — | R 649 | 21d | — | — | ~6 | ~R 3 893 indirect | — |
Cytarabine monotherapy Variant #01 | — | R 357 | 30d | — | — | ~2 | ~R 713 indirect | — |
Ibritumomab tiuxetan protocol Variant #18 Partial | — | — | 8d | ~36.5 mo | — | ~1 | — | 1 |
Radiation therapy N/A - radiation | — | — | 49d | — | — | — | — | 1 |
Placebo Partial | — | — | — | 58.9 mo | — | — | — | 1 |
TBI Variant #01 | — | — | — | — | — | — | — | 2 |
Observation Partial | — | — | — | — | ~37.1 mo | — | — | 3 |
Methotrexate monotherapy Partial | — | — | — | ~2.6 mo | ~6.7 mo | — | — | 10 |
13 of 13 regimens shown